Buprenorphine is used for opioid use disorder (OUD) maintenance therapy. It has a 'ceiling effect' for respiratory depression but NOT for analgesia. The pharmacological basis for this is:

• A Buprenorphine's very slow receptor dissociation (tight binding) keeps receptors occupied without progressive activation
• B As a partial mu agonist, buprenorphine cannot recruit the full G-protein/arrestin signaling needed for respiratory depression even at full receptor occupancy, unlike full agonists which increase recruitment proportionally with dose ✓
• C Buprenorphine crosses the BBB poorly, limiting CNS respiratory depression while allowing peripheral analgesia
• D Buprenorphine co-activates kappa receptors which antagonize mu-mediated respiratory depression

Explanation

Buprenorphine is a partial mu opioid agonist (intrinsic efficacy < 1). While it has high receptor affinity and slow dissociation, the ceiling effect for respiratory depression occurs because at maximum receptor occupancy a partial agonist cannot generate the full downstream signaling cascade (including beta-arrestin recruitment linked to respiratory depression) that full agonists do. However, the analgesic signaling pathway appears to reach near-maximal response with partial activation, so analgesia does not exhibit the same ceiling. This biased signaling concept is relevant to newer opioid development.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.